Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: bmaz001 who wrote (546)	12/18/2019 9:47:03 PM
From: scaram(o)uche	Respond to of 684

Given recidivism, a market that would just keep on giving. Your parents should have spiked your beer with RTB101. Thanks for engaging us after my Q. Rare at S.I. these days. And, again, thanks for what you're doing for all of us. Rick

To: bmaz001 who wrote (546)	12/19/2019 3:15:02 AM
From: BulbaMan	1 Recommendation Recommended By bmaz001 Read Replies (1) \| Respond to of 684

ADRO is another cash rich biotech I’m considering for the 2020 SI Charity Contest. Roughly, both market cap & cash of ADRO are twice that of TORC. (FD: I own ADRO in real life.) By the way, the 2020 Contest Board is up and ready for portfolio submissions: Subject 60090 Peace & good health, Bulba

To: bmaz001 who wrote (546)	1/29/2020 3:07:07 PM
From: scaram(o)uche	Respond to of 684

Didn't know at the time of this discussion that RTB101 is also a pan-PI3K inhibitor. Have no interest, and thought that I should pop in and mention such. Took a loss and have moved on. Wrote the company asking for some (any!) information (location, regulatory jurisdiction) concerning their Parkinson's trial and/or any RTB101 trial in combo with rapalog. Got no response. mTORC1 inhibitors have great promise, given pre-clinical observations. Hope that the company can ultimately succeed.